Management of a patient with subacute tricuspid valve and pacemaker endocarditis with chronic thromboembolic pulmonary hypertension: a case report
https://doi.org/10.15829/1560-4071-2023-5501
EDN: ZROONY
Abstract
A case report is devoted to the successful management of a 33-year-old patient with subacute infective endocarditis of the tricuspid valve and pacemaker, as well as chronic thromboembolic pulmonary hypertension. There were following therapy stages: 1) pharmacotherapy — antimicrobial agents, treatment of heart failure, pulmonary hypertension; 2) an interventional approach — tricuspid valve replacement with chamber sanitation, pacemaker explantation, endocardial lead removal from the right heart, implantation of a pacemaker with an epicardial lead system and 3) delayed balloon pulmonary angioplasty.
About the Authors
N. V. Chumachenko
Research Institute — Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
N. V. Kizhvatova
Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
E. D. Kosmacheva
Research Institute — Ochapovsky Regional Clinical Hospital № 1; Kuban State Medical University
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
Z. G. Tatarintseva
Research Institute — Ochapovsky Regional Clinical Hospital № 1
Russian Federation
Competing Interests:
Russian Federation
Krasnodar
Competing Interests:
none
References
1. Blinova VV, Panteleeva EA, Mironova AA, et al. Pulmonary embolism as a complication of permanent electrocardiostimulation. Practical medicine. 2020;18(1):116-9. (In Russ.) doi:10.32000/2072-1757-2020-1-116-119.
2. Humbert M, Kovacs G, Hoeper MM, et al. ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-731. doi:10.1093/eurheartj/ehac237.
3. Noheria A, Ponamgi SP, Desimone CV, et al. Pulmonary embolism in patients with transvenous cardiac implantable electronic device leads. Europace. 2016;18(2):246-52. doi:10.1093/europace/euv038.
4. Liesenborghs L, Meyers S, Vanassche T, et al. Coagulation: At the heart of infective endocarditis. J Thromb Haemost. 2020;18(5):995-1008. doi:10.1111/jth.14736.
5. Martyniuk TV, Dadacheva ZK, Chazova IE. Possibilities of medical treatment of chronic thromboembolic pulmonary hypertension. Aterotromboz. 2015;(1):87-98. (In Russ.) doi:10.21518/2307-1109-2015-1-30-40.
6. Makarova NV, Busalaeva EI, Tuizarova IA, et al. Difficulties in diagnosing pulmonary embolism in clinical practice. Ulianovskii mediko-biologicheskii zhurnal. 2022;(3):35-42. (In Russ.) doi:10.34014/2227-1848-2022-3-35-42.
7. Konstantinides S, Meyer G, Becattini C, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543603. doi:10.1093/eurheartj/ehz405.
8. Zotova IV, Zateyshchikov DA. Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice. Russian Journal of Cardiology. 2020;25(S3):4024. (In Russ.) doi:10.15829/1560-4071-2020-4024.
9. Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respiratory Review. 2017;26:160112. doi:10.1183/16000617.0112-2016.
10. Noshak MA, Rezaee MA, Hasani А, et al. The Role of the Coagulase-negative Staphylococci (CoNS) in Infective Endocarditis; A Narrative Review from 2000 to 2020. Curr Pharm Biotechnol. 2020;21(12):1140-53. doi:10.2174/1389201021666200423110359.
11. Panchenko EP, Balahonova TV, Danilov NM, et al. Diagnosis and Management of pulmonary embolism: Eurasian Association of Cardiology (EAC) Clinical Practice Guidelines (2021). Eurasian heart journal. 2021;(1):44-77. (In Russ.) doi:10.38109/2225-1685-2021-1-44-77.
12. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.
13. Karyofyllis P, Demerouti E, Giannakoulas G, et al. Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension in Greece: Data from the Hellenic Pulmonary Hypertension Registry. J. Clin. Med. 2022;11(8):2211. doi:10.3390/jcm11082211.
14. Karabasheva MB, Danilov NM, Sagaidak OV, et al. Dynamics of ECG indicators in patients with chronic thromboembolic pulmonary hypertension after transluminal pulmonary balloon angioplasty. Systemic Hypertension. 2019;16(2):28-31. (In Russ.) doi:10.26442/2075082X.2019.2.190180.
15. Golukhova EZ, Slivneva IV, Mamalyga ML, et al. Right ventricular free-wall longitudinal speckle tracking strain as a prognostic criterion of adverse outcomes in patients with pulmonary hypertension: a systematic review and meta-analysis. Russian Journal of Cardiology. 2021;26(4):4417. (In Russ.) doi:10.15829/15604071-2021-4417.
Supplementary files
- The presence of a pacemaker is a risk factor for pulmonary embolism.
- Conservative management of pacemaker infective endocarditis is ineffective. Sepsis plays the role of a trigger for hypercoagulation.
- In case of distal pulmonary artery involvement and technical feasibility, staged balloon pulmonary angioplasty with pre- and postoperative personalized therapy is advisable.
Review
For citations:
Chumachenko N.V., Kizhvatova N.V., Kosmacheva E.D., Tatarintseva Z.G. Management of a patient with subacute tricuspid valve and pacemaker endocarditis with chronic thromboembolic pulmonary hypertension: a case report. Russian Journal of Cardiology. 2023;28(4S):5501. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5501. EDN: ZROONY
Views:
587
Email this article 